Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/4895sf22

ARTIFICIAL INTELLIGENCE IN FORMULATION DESIGN A NEW ERA IN PHARMACEUTICS

Aryan Patel[1], Dr. Shweta Paroha[2*], Dr. Pragnesh Patani[3]

[1*,2,3]khyati College of Pharmacy, Palodia, Ahmedabad

***Corresponding Author:** Dr. Shweta Paroha
*Khyati College of Pharmacy, Palodia, Ahmedabad, Email: shwetatechno86@gmail.com

ABSTRACT:
The pharmaceutical business is undergoing a transformation thanks to formulation design and the incorporation of artificial intelligence (AI) into drug development. Drug research, formulation development, manufacturing, quality control, and post-market surveillance are just a few of the areas in the pharmaceutical business that have seen a paradigm shift as a result of the introduction of artificial intelligence (AI). By evaluating large datasets to improve formulations and forecast patients behavior's, these technologies make precision medicine accessible. AI-powered models improve the stability, bioavailability, and pinpoint precision of therapeutic agents based on nanoparticles. By streamlining the development and research processes, AI can help lower the price of development. In addition to predicting the pharmacokinetics and toxicity of potential drugs, machine learning techniques aid in the design of experiments. By selecting and optimizing lead compounds, this capability lessens the need for expensive and time-consuming animal testing. The rapid expansion of biomedical data offers benefits for using AI at every level of drug research and development. When AI is successfully used and integrated into multiple steps, the pharmaceutical sector needs to solve a number of inherent limitations and problems.



Figure 1. GRAPHICAL ABSTRACT

1. INTRODUCTION:

A new age in research is brought about by information technology, which speeds up the creation of therapeutic targets and vaccines, enhances validation techniques, facilitates the identification of adverse effects, and predicts drug resistance.[1] Numerous scientific, technological, and managerial aspects that should improve the effectiveness of commercial drug research and development (R&D) have advanced significantly during the last 60 years.[2] The data can be examined using a variety of techniques and technologies, the most common and widely used of which are artificial neural networks (ANN), fuzzy logic, neuro-fuzzy logic, and genetic algorithms.[3] After decades of growth and development, AI could boost pharmaceutical logistics management.[4]



Figure 2. FEATURES OF AI IN PHARMACEUTICS

2. HISTORY OF AI IN FORMULATION DESIGN:

Bradshaw made the first known mention of the application of expert systems in the creation of medicinal products on April 27, 1989, in the London.[5] In the 1990s, artificial intelligence (AI) was initially used in drug product development to forecast immediate-release oral tablet properties including disintegration time and dissolve rate using neural networks.[6] Two major categories of advancements in AI technology exist. The first one consists of traditional computing techniques, such as expert systems, which may both illustrate the conclusions drawn from the principles and simulate human experience. The second one consists of systems that use artificial neural networks (ANNs) to simulate how the brain functions.[7] In an effort to create better healthcare solutions, many pharmaceutical companies have invested in and formed joint ventures with AI startups as a result of the rapid introduction of AI in healthcare, particularly in 2016 and 2017.[8] The McKinsey Global Institute claims that the quick development of AI-guided automation would drastically change how society perceives work. Every phase of a pharmaceutical product's life cycle, including drug discovery, optimization, formulation development, characterisation, quality testing, marketing, and post-marketing surveillance, can benefit from the application of AI.[9] Formulation AI offers pharmaceutical scientist’s fresh concepts and technological tools to tackle drug delivery issues.[10]

3. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICS:

In several disciplines, artificial intelligence (AI) is driving research and application. AI aids in the development, discovery, and distribution of pharmaceuticals in pharmacies. With individualized treatment regimens, it can improve patient care.[11] AI technology has the power to revolutionize how pharmacy teams and pharmacists operate. In order to enhance the safe and efficient administration of medications in any environment and improve patient outcomes, the RPS encourages the responsible and efficient application of AI in healthcare settings, including pharmacy services.[12] AI encompasses a number of approach disciplines, including machine learning (ML), a foundational paradigm, reasoning, knowledge representation, and solution search. Deep learning (DL), a subset of machine learning (ML), leverages artificial neural networks (ANNs) to identify and interpret complex patterns within categorized data. These are made up of a number of connected, very sophisticated computer elements that use "perceptions" that are similar to biological neurons to mimic how electrical impulses are sent in the human brain.[13] According to studies, the deep neural network (DNN), a subset of artificial neural networks (ANN), performs quite similarly to in-vitro tests. Machine learning (ML), a component of artificial intelligence, has been successful mostly due to the availability of massive datasets and advancements in information technology, which provide an excellent platform for training the equipment. To achieve the greatest performance and high-quality output, ANN and ML are combined. This ANN system, which consists of convolutional neural networks (CNN), recurrent neural networks (RNN), and DNN, is what propels the development of AI. In the pharmaceutical business, this DNN shows a high level of accuracy in forecasting medication properties. It feeds forward data flow from the input to the hidden layer to the output layer. Inspired by the human brain, an artificial neural network (ANN) is made up of several nodes, also known as neurons, from which signals travel to the hidden layer, which is the next layer before output. There are connections between these neurons or several nodes. The primary drawback of ANNs is the potential for excess and unknown descriptors to choke the output.[141516]



Figure 3. ARTIFICIAL INTELLIGENCE: MACHINE LEARNING

4. APPLICATION OF AI IN FORMULATION DESIGN:

4.1 PREFORMULATION STUDIES:

(1)Prediction of physiochemical properties:

Drug efficacy is significantly impacted by important preformulation factors as solubility, particle size, pKa, hygroscopicity, and polymorphism. These parameters may now be quickly assessed and predicted thanks to AI-enabled models, especially those based on machine learning, which lessens the need for lengthy experimental trials.[17]

(2)Computational screening of excipients:

Interactions between drugs and excipients may result in decreased efficacy or stability problems. AI systems can forecast unfavorable interactions and direct selection toward excipient combinations that work well together by using compatibility databases.[18] Stability and dissolution behavior are impacted by polymorphic variation. Stable polymorphs that satisfy pharmacological and regulatory requirements can be found using deep learning systems that have been trained on crystallographic and thermodynamic data.[19]

4.2 DRUG-EXCIPIENT COMPATIBILITY:

(1)Drug – excipient stability and interaction:

AI has also shown potential in predicting drug-excipient interactions, which are an important part of preformulation. Incompatibilities may lead to degradation, reduced efficacy, or altered bioavailability. ML models trained on historical formulation data can categorize excipients as compatible or incompatible, taking into account profiles of molecular interactions as well as environmental characteristics like temperature and humidity.[20] For example, Bayesian networks and decision trees have been used to assess stability concerns by looking at deterioration kinetics under various stress circumstances. Studies have shown that integrating cheminformatics and AI can help identify excipients that may catalyze oxidation or hydrolysis processes.[21,22]
(2)Expediting the process of choosing an excipient combination:

To predict the properties and behavior of excipients, supervised learning models such as ANNs, decision trees, and SVM are commonly employed among AI techniques. For example, ANN models can be trained on historical formulation datasets to predict the optimal concentrations of binders, disintegrants, or surfactants based on target disintegration time, compressibility, and dissolving rate.[23,24]

4.3 OPTIMIZING FORMULATION:

(1)AI as Design of Experiment:
Numerous factors, such as the physicochemical characteristics of the drug, interactions between excipients, and process parameters, are involved in the development of pharmaceutical formulations. Historically, this has depended on statistical methods like DoE or empirical methods like trial-and-error. However, these methods often fail when the formulation space becomes multidimensional and highly complex. AI, particularly machine learning (ML), provides a powerful alternative by facilitating pattern identification, predictive modelling, and data-driven decision-making, so enabling robust formulation optimization.[25]

(2)Predictive modelling for formulation:
RF, SVMs, ANNs, and genetic algorithms (GAs) are among the machine learning (ML) methods that have been thoroughly studied in the optimization of medication formulations. Large datasets can be analyzed using these models to uncover complex non-linear correlations between formulation inputs (such as process factors and excipient type and concentration) and outputs (such as stability, bioavailability, and dissolution rate), which are typically difficult to capture with conventional approaches.[26]
(3)Artificial Intelligence in Nanomedicine:

Through the utilization of artificial intelligence (AI) in data analysis, pattern recognition, and optimization, researchers in nanomedicine can expedite the creation of innovative nanoscale interventions, optimize medication delivery, improve diagnostics, and promote customized medicine. Because AI in nanomedicine makes precise and tailored therapeutic techniques possible at the nanoscale, it has enormous potential to transform healthcare.[27] The applications of nanoparticles include sensing, imaging, and targeted medicine delivery. By forecasting the stability, efficacy, and physicochemical characteristics of nanoparticles, artificial intelligence algorithms can help in their design and optimization. Nanomedicines, built on the concept of synergistic therapy, serve as advanced carriers for delivering drugs or drug combinations, particularly in cancer treatment. Their design is shaped by key considerations such as the use of stimuli-responsive materials, the selection of therapeutic agents, and the optimization of dosing strategies. This helps scientists create nanoparticles with the desired properties for specific applications. Melanoma was treated with a deep learning system, which has demonstrated excellent accuracy in patient care and diagnostic process support.[28,29]

4.4 AI in personalized medication:

Precision medicine, another name for personalized medicine, is a quickly developing medical field that aims to tailor treatment by considering each patient's distinct molecular, physiological, ecological, and behavioral traits.[30]

Instead of using a one-size-fits-all strategy to illness prevention and treatment, personalized medicine aims to customize therapies for each patient. When the human genome was fully sequenced in 2003, personalized medicine advanced beyond the genome to encompass the whole field of molecular medicine. Personalized medicine has greatly benefited from technological advancements including wireless health monitoring devices, imaging procedures, and DNA proteomics. There are still obstacles to be addressed, though, like the requirement for more pertinent models derived from human cell cultures and the customization of treatment.[31] The adoption of artificial intelligence (AI) in pharmacogenomics is fueled by its promise to transform patient care and improve therapeutic outcomes. Through the lens of personalized medicine, AI makes it possible to account for an individual's distinct biological makeup, physiological traits, environmental influences, and behavioral patterns, paving the way for highly tailored treatment strategies.[32]



Figure 4. AI IN PERSONALIZED MEDICATION

5. CASE STUDIES OF ARTIFICIAL INTELLIGENCE IN FORMULA DEVELOPMENT:

Large pharmaceutical corporations are using AI to detect failure mechanisms, mitigate risk before commercialization, reduce development times by up to 50%, identify stable drug candidates early, and check quality in real-time under QbD frameworks.[33]

The use of machine learning (ML)-based models, or intelligent models, is a recent development in the field of PDDS release profile prediction. These models primarily use machine learning and soft computing techniques, which have shown impressive performance in interpreting complex interrelationships and identifying sophisticated data patterns.[34,35]

Depending on whether labeled output data is available during the training stage, machine learning models can be divided into two main categories:

- Supervised learning: In supervised learning, models are trained on datasets where the correct outputs are already known. Through studying the relationship between inputs and their corresponding outputs, the model develops a function capable of predicting results for data it has never encountered before.
- Unsupervised learning: Unlabeled data is used by unsupervised machine learning models, which enable them to identify natural data structures and, as a result, classify input samples into discrete clusters without the need of labels.[36,37]

5.1 AI IN COVID-19 SITUATION:

The 2019 coronavirus disease (COVID-19) pandemic has severely strained public health infrastructure, health systems, and the economies of several nations. The novel coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2) was the cause.[38] As of March 2021, the World Health Organization had received reports of 119,220,681 confirmed cases of COVID-19 worldwide, including 2,642,826 fatalities. There were 223 impacted nations, regions, or territories. To avoid SARS-CoV-2, billions of people stayed at home. At the same time, numerous issues surfaced.[39] AI has significantly raised our level of diagnosis, prediction, and treatment in the fight against COVID-19.[40]

As COVID-19 patients were being treated, the illness quickly evolved. In a short amount of time, several re-examinations were necessary, producing a large amount of medical data. Clinicians find it very challenging to diagnose COVID-19 accurately and quickly because of these issues. Large amounts of test data may be swiftly analyzed by AI to identify possible COVID-19 patients. Additionally, it rapidly assesses the progression of the disease, compares the patient's state before and after the illness in detail, and measures the extent of lung damage. These pieces precisely support the physician's diagnosis.[41,42]



Figure 5. AI IN COVID-19

6. ADVANTAGES OF AI IN FORMULATION DESIGN:

Drug Discovery and Design: The activity or characteristics of novel drug candidates can be predicted using supervised learning techniques. The model can discover patterns and connections between molecular characteristics and intended results by being trained on a collection of well-known chemicals and the actions that go along with them. This helps in drug discovery and design by making it possible to anticipate the activity, potency, or toxicity of novel molecules.[43]

Drug Target Identification: By examining biological data, supervised learning algorithms can assist in identifying possible drug targets. The model can learn patterns and pinpoint possible areas for additional research by being trained on data that includes details on genetic, proteomic, or transcriptomic characteristics and how they connect to the way a disease progresses or how well a medication works.[44]

Adverse Event Detection: Pharmacovigilance data can be subjected to supervised learning algorithms in order to detect and categorize drug-related adverse events. The algorithm can detect and characterize adverse events by learning to identify trends and possible safety signals by training on labeled adverse event reports.[45]

AI in drug discovery like

- Virtual Screening
- Structure-Activity Relationship (SAR) Modelling

- Optimization of Drug Candidates
- Drug Repurposing

All things considered, AI-driven methods in drug research and development have the potential to simplify and accelerate the discovery, refinement, and creation of innovative therapeutic candidates, which will ultimately result in more effective and efficient drugs. [46]



Figure 6. ADVANTAGES OF AI

7. CHALLENGES AND LIMITATION:

While artificial intelligence (AI) is gaining popularity in pharmaceutical sciences, several barriers and limitations hinder its smooth integration into formulation development, ranging from data-related issues to interpretability and regulatory concerns, especially when AI is applied to excipient selection and optimization.[47] Another major barrier is that many AI models, especially DL networks, are "black-box" in nature, meaning that while they are very good at predicting outcomes, their decision-making process is often opaque, making it difficult for pharmaceutical scientists and regulatory agencies to trust AI-generated formulation decisions because they are difficult to interpret if theydo not understand the reasoning behind them.[48]

Integration with existing pharmaceutical workflows is another logistical challenge. Traditional fo rmulation development relies primarily on expert intuition and experimental methods, and many institutions are hesitant to invest in retraining personnel, redesigning workflows, and altering leg acy systems in order to incorporate AI into these processes because there are no guarantees of ret urns.[49] Additionally, regulatory agencies such as the FDA and EMA are still developing guidelines for AI and ML in drug development, and it is still unclear whether regulations will accept formulations aided by AI. The lack of standardized validation processes, along with problems with data provenance, model retraining, and reproducibility, is hindering regulatory confidence in AI outputs.[47]

The challenges of AI-powered pharmacogenomics are numerous and have been covered in a number of articles. These difficulties include the requirement for data security, the integration of heterogeneous data, the need for visible and explicable models, and the difficulty of getting enough pharmacogenomic data for model building, the difficulty of connecting different drug layers, and the requirement for accurate predictions.[50–54]

Figure 7. CHALLENGES OF AI

8. FUTURE PRESPECTIVES:

The way medications are utilized to treat individual individuals is being revolutionized by new developments in pharmacogenomics and artificial intelligence.[55]

Artificial Intelligence (AI) in pharmaceutical formulation science is expected to make significant strides, impacting a future where drug delivery and design become more patient-centered, accurate, and fast. One of the most exciting developments is the development of digital twins, or virtual copies of real formulation systems, which eliminate the need for long experimental trials by simulating the performance and stability of formulations in real time under various situations.

Digital twins are increasingly being studied in continuous manufacturing settings, where AI-enabled real-time feedback loops can dynamically optimize formulation variables.[56] Artificial intelligence is being used more and more frequently in healthcare across a range of domains, from diagnosis to clinical risk assessment and screening.[57]



Figure 8. AI IN FORMULATION DESIGN

Looking ahead, AI holds promise for personalized formulations and real-time adjustments through integration with lab automation systems. Regulatory bodies are also investigating validation frameworks for AI-based evidence submission. Despite the advancements, a number of challenges remain, including data integrity, interpretability, collaborative gaps, and changing regulatory frameworks.[5859]

9. CONCLUSION:

AI-driven predictive modeling, machine learning algorithms, and data-centric design strategies are complementing and, in some cases, redefining traditional formulation approaches, which often rely on extensive trial-and-error methods. AI represents a revolutionary shift in the conception, development, and optimization of pharmaceutical products by enabling the rapid screening and selection of excipients, the prediction of formulation stability, and the identification of critical material properties and process parameters through the use of big datasets and sophisticated algorithms. AI in pre-formulation and formulation enables the creation of customized dosage forms based on pharmacogenomic profiles, patient-specific information, and therapeutic requirements. Despite these advancements, challenges remain. The "black-box" character of many machine learning models, data quality, and algorithm interpretability is some of the obstacles to broader industrial usage. Collaboration between data scientists, pharmaceutical experts, and regulatory stakeholders is essential to bridging these gaps.

In conclusion, with responsible use and interdisciplinary collaboration, artificial intelligence (AI) has great promise for pharmaceutical formulation research, particularly for excipient optimization, and could herald in a new era of ingenious, efficient, and patient-centered medication discovery.

REFERENCES:

1. Chavda, V., Anand, K. & Apostolopoulos, V. *Bioinformatics Tools for Pharmaceutical Drug Product Development*. (2023).
2. Scannell, J. W., Blankley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat Rev Drug Discov* **11**, 191–200 (2012).
3. Ali, K. A. *et al.* Influence of artificial intelligence in modern pharmaceutical formulation and drug development. *Future Journal of Pharmaceutical Sciences 2024 10:1* **10**, 1–15
4. (2024).
5. Joshi, A. *et al.* Role of artificial intelligence in pharmaceutical drug development and drug delivery: An updated review. *Current Trends in Pharmacy and Pharmaceutical Chemistry* **7**, 35–49 (2025).
6. Rowe, R. C. & Roberts, R. J. Artificial intelligence in pharmaceutical product formulation: knowledge-based and expert systems. *Pharm Sci Technol Today* **1**, 153–159 (1998).
7. Huanbutta, K. *et al.* Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. *European Journal of Pharmaceutical Sciences* **203**, 106938 (2024).
8. Das, S., Dey, R. & Kumar Nayak, A. Artificial Intelligence in Pharmacy. *Indian Journal of Pharmaceutical Education and Research* | **55**,.
9. Mak, K. K. & Pichika, M. R. Artificial intelligence in drug development: present status and future prospects. *Drug Discov Today* **24**, 773–780 (2019).
10. Ali, K. A. *et al.* Influence of artificial intelligence in modern pharmaceutical formulation and drug development. *Future Journal of Pharmaceutical Sciences 2024 10:1* **10**, 1–15
11. (2024).
12. Dong, J., Wu, Z., Xu, H. & Ouyang, D. FormulationAI: a novel web-based platform for drug formulation design driven by artificial intelligence. *Brief Bioinform* **25**, (2023).
13. Vora, L. K. *et al.* Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics* **15**, 1916 (2023).
14. González-Pérez, Y., Montero Delgado, A. & Martinez Sesmero, J. M. Acercando la inteligencia artificial a los servicios de farmacia hospitalaria. *Farmacia Hospitalaria* **48**, S35–S44 (2024).
15. Paul, D. *et al.* Artificial intelligence in drug discovery and development. *Drug Discov Today* **26**,

80 (2020).
16. Hessler, G. & Baringhaus, K. H. Artificial Intelligence in Drug Design. *Molecules 2018, Vol. 23, Page 2520* **23**, 2520 (2018).
17. Patel, L., Shukla, T., Huang, X., Ussery, D. W. & Wang, S. Machine Learning Methods in Drug Discovery. *Molecules 2020, Vol. 25, Page 5277* **25**, 5277 (2020).
18. Ahuja, A. S. & Schmidt, C. E. The impact of artificial intelligence in medicine on the future role of the physician. *PeerJ* **7**, e7702 (2019).
19. Witten IH, Frank E, Hall MA, Pal CJ. Data Mining: Practical Machine Learning Tools and Techniques. 4th ed. Elsevier; 2016. - Google Search. https://www.google.com/search?q=Witten+IH%2C+Frank+E%2C+Hall+MA%2C+Pal+CJ.+
20. Data+Mining%3A+Practical+Machine+Learning+Tools+and+Techniques.+4th+ed.+Elsevie r%3B+2016.&rlz=1C1CHBF_enIN1142IN1142&oq=Witten+IH%2C+Frank+E%2C+Hall+MA
21. %2C+Pal+CJ.+Data+Mining%3A+Practical+Machine+Learning+Tools+and+Techniques.+4t h+ed.+Elsevier%3B+2016.&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRiPAjIHCAIQI RiP AjIHCAMQIRiPAtIBCDEzODJqMGo3qAIIsAIB8QXtVpopHCzhsvEF7VaaKRws4bI&sourcei d=c hrome&ie=UTF-8.
22. Avdeef, Alex. Absorption and drug development : solubility, permeability, and charge
23. state. 287 (2003).
24. Taylor, C. R. *et al.* Minimizing polymorphic risk through cooperative computational and experimental exploration. *J Am Chem Soc* **142**, 16668–16680 (2020).
25. Vora, L. K. *et al.* Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics 2023, Vol. 15, Page 1916* **15**, 1916 (2023).
26. Cheng, F. & Zhao, Z. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. *J Am Med Inform Assoc* **21**, (2014).
27. Ceschan, N. E. *et al.* Development of a Carrier-Free Dry Powder Ofloxacin Formulation With Enhanced Aerosolization Properties. *J Pharm Sci* **109**, 2787–2797 (2020).
28. Hamid, J. U. & Gupta, S. Development and validation of a system for the prediction of excipient-excipient incompatibility using machine learning tools. *Pharmaspire* **14**, 18–27 (2022).
29. Patel, S., Patel, M., Kulkarni, M. & Patel, M. S. DE-INTERACT: A machine-learning-based predictive tool for the drug-excipient interaction study during product development—Validation through paracetamol and vanillin as a case study. *Int J Pharm* **637**, (2023).
30. Muneer, R., Hashmet, M. R., Pourafshary, P. & Shakeel, M. Unlocking the Power of Artificial Intelligence: Accurate Zeta Potential Prediction Using Machine Learning. *Nanomaterials* **13**, 1209 (2023).
31. Öztürk, K., Kaplan, M. & Çalış, S. Effects of nanoparticle size, shape, and zeta potential on
32. drug delivery. *Int J Pharm* **666**, (2024).
33. Chavda, Vivek., Krishnan, Anand. & Apostolopoulos, Vasso. Bioinformatics tools for pharmaceutical drug product development. (2023).
34. Ho, D., Wang, P. & Kee, T. Artificial intelligence in nanomedicine. *Nanoscale Horiz* **4**, 365–377 (2019).
35. Zarrinpar, A. *et al.* Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. *Sci Transl Med* **8**, (2016).
36. Rykov, M. Yu. & Ю., P. M. The evolution of personalized medicine: publications review.
37. *Problems of Social Hygiene, Public Health and History of Medicine* **30**, 1211–1219 (2022).
38. Visvikis-Siest, S., Theodoridou, D., Kontoe, M. S., Kumar, S. & Marschler, M. Milestones in Personalized Medicine: From the Ancient Time to Nowadays—the Provocation of COVID-
39. 19. *Front Genet* **11**, (2020).
40. Bezdieniezhnykh, N., … V. R.-E. & 2017, undefined. Scientific-practical and legal problems of implementation of the personalized medicine. *dspace.nbuv.gov.uaNO Bezdieniezhnykh, VV*

Reznikova, OV RossylnaExperimental Oncology, 2017•dspace.nbuv.gov.ua **39**, 229–233 (2017).
41. Stokes, J. M. *et al.* A Deep Learning Approach to Antibiotic Discovery. *Cell* **180**, 688- 702.e13 (2020).
42. Alpaydin, E. *Introduction to Machine Learning*. (2020).
43. IEEE Xplore Full-Text PDF: https://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=10115411&utm_source=sciencedirect_contenthosting&getft_integrator=sciencedirect_contenthosting.
44. Ansari, M. Y., Qaraqe, M., Righetti, R., Serpedin, E. & Qaraqe, K. Enhancing ECG-based heart age: impact of acquisition parameters and generalization strategies for varying signal morphologies and corruptions. *frontiersin.orgMY Ansari, M Qaraqe, R Righetti, E Serpedin, K QaraqeFrontiers in Cardiovascular Medicine, 2024•frontiersin.org* **11**, (2024).
45. Ansari, M. Y. *et al.* Towards developing a lightweight neural network for liver CT segmentation. *SpringerMY Ansari, S Mohanty, SJ Mathew, S Mishra, SS Singh, J Abinahed, A Al-Ansari, SP DakuaInternational Conference on Medical Imaging and Computer-Aided Diagnosis, 2022•Springer* **810 LNEE**, 27–35 (2023).
46. Budd, J. *et al.* Digital technologies in the public-health response to COVID-19. *Nat Med* **26**, 1183–1192 (2020).
47. Kinoshita, R. *et al.* Containment, contact tracing and asymptomatic transmission of novel coronavirus disease (Covid-19): A modelling study. *J Clin Med* **9**, 1–9 (2020).
48. Bragazzi, N. L. *et al.* How big data and artificial intelligence can help better manage the covid-19 pandemic. *Int J Environ Res Public Health* **17**, (2020).
49. Brinati, D. *et al.* Detection of COVID-19 Infection from Routine Blood Exams with Machine Learning: A Feasibility Study. *J Med Syst* **44**, (2020).
50. Li, W. T. *et al.* Using machine learning of clinical data to diagnose COVID-19: A systematic review and meta-analysis. *BMC Med Inform Decis Mak* **20**, (2020).
51. Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M. & Ahsan, M. J. Machine Learning in Drug Discovery: A Review. *Artificial Intelligence Review 2021 55:3* **55**, 1947–1999 (2021).
52. Bagherian, M. *et al.* Machine learning approaches and databases for prediction of drug- target interaction: a survey paper. *Brief Bioinform* **22**, 247–269.
53. Chapman, A. B. *et al.* Detecting Adverse Drug Events with Rapidly Trained Classification Models. *Drug Saf* **42**, 147–156 (2019).
54. Shah, H., Chavda, V. & Soniwala, M. M. Applications of bioinformatics tools in medicinal biology and biotechnology. *Wiley Online LibraryH Shah, V Chavda, MM Soniwala Bioinformatics tools for pharmaceutical drug product development, 2023•Wiley Online Library* 95–116 (2023) doi:10.1002/9781119865728.CH6.
55. Kant, S., Deepika, · & Roy, · Saheli. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. *Discover Pharmaceutical Sciences 2025 1:1* **1**, 1–14 (2025).
56. Malheiro, V., Santos, B., Figueiras, A. & Mascarenhas-Melo, F. The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials. *Pharmaceuticals 2025, Vol. 18, Page 788* **18**, 788 (2025).
57. Mansur, M. A. Artificial Intelligence in Drug Discovery Towards Strategic Applications Challenges and Implementation Frameworks for Accelerated Pharmaceutical Innovation. *European Journal of Artificial Intelligence and Machine Learning* **4**, 16–23 (2025).
58. Chang, W. C., Tanoshima, R., Ross, C. J. D. & Carleton, B. C. Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings. *Annu Rev Pharmacol Toxicol* **61**, 65–84 (2021).
59. Kumar, M. *et al.* Opportunities and challenges in application of artificial intelligence in pharmacology. *Pharmacological Reports 2023 75:1* **75**, 3–18 (2023).
60. Wei, W., Zhao, J., … D. R.-C. pharmacology & 2021, undefined. Machine learning challenges in pharmacogenomic research. *pmc.ncbi.nlm.nih.govWQ Wei, J Zhao, D Roden, JF PetersonClinical pharmacology and therapeutics, 2021•pmc.ncbi.nlm.nih.gov*.

61. Primorac, D. *et al.* Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. *Taylor & FrancisD Primorac, L Bach-Rojecky, D Vađunec, A Juginović, K Žunić, V Matišić, A Skelin, B ArsovPharmacogenomics, 2020•Taylor & Francis* **21**, 141–156 (2020).
62. Kalinin, A. A. *et al.* Deep learning in pharmacogenomics: from gene regulation to patient stratification. *Taylor & FrancisAA Kalinin, GA Higgins, N Reamaroon, S Soroushmehr, A Allyn-Feuer, ID Dinov, K NajarianPharmacogenomics, 2018•Taylor & Francis* **19**, 629–650 (2018).
63. Taherdoost, H. & Ghofrani, A. AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. *Intelligent Pharmacy* **2**, 643–650 (2024).
64. Sajadieh, S. M. M. & Noh, S. Do. From Simulation to Autonomy: Reviews of the Integration of Artificial Intelligence and Digital Twins. *International Journal of Precision Engineering and Manufacturing - Green Technology* (2025) doi:10.1007/S40684-025- 00750-Z.
65. Pokhriyal, P., Chavda, V. P. & Pathak, M. Future Prospects and Challenges in the Implementation of AI and ML in Pharma Sector. *Wiley Online LibraryP Pokhriyal, VP Chavda, M PathakBioinformatics tools for pharmaceutical drug product development, 2023•Wiley Online Library* 401–416 (2023) doi:10.1002/9781119865728.CH17.
66. Levin, S. *et al.* Machine-Learning-Based Electronic Triage More Accurately Differentiates Patients With Respect to Clinical Outcomes Compared With the Emergency Severity Index. *Ann Emerg Med* **71**, 565-574.e2 (2018).
67. Artificial Intelligence in Software as a Medical Device | FDA. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial- intelligence-software-medical-device.